LON:AZN - AstraZeneca Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 5,856 +32.00 (+0.55 %) (As of 05/21/2019 07:40 AM ET)Previous CloseGBX 5,824Today's RangeGBX 5,810 - GBX 5,87952-Week RangeGBX 5,110 - GBX 6,540Volume402,376 shsAverage Volume2.31 million shsMarket Capitalization£76.82 billionP/E Ratio30.82Dividend Yield3.76%BetaN/A ProfileAnalyst RatingsChartDividendInsider TradesHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. Receive AZN News and Ratings via Email Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Major Sub-IndustryN/A SectorMedical Current SymbolLON:AZN Previous Symbol CUSIPN/A CIKN/A Webwww.astrazeneca.com Phone+44-20-73045000Debt Debt-to-Equity Ratio179.66 Current Ratio0.75 Quick Ratio0.57Price-To-Earnings Trailing P/E Ratio30.82 Forward P/E Ratio15.33 P/E GrowthN/A Sales & Book Value Annual Sales£22.40 billion Price / Sales3.43 Cash FlowGBX 388.89 per share Price / Cash Flow15.06 Book ValueGBX 799.20 per share Price / Book7.33Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees64,400 Outstanding Shares1,311,760,000Market Cap£76.82 billion Next Earnings Date7/25/2019 (Estimated) OptionableOptionable AstraZeneca (LON:AZN) Frequently Asked Questions What is AstraZeneca's stock symbol? AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN." How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca? AstraZeneca declared a dividend on Thursday, February 14th. Investors of record on Thursday, February 28th will be paid a dividend of GBX 146.80 per share on Wednesday, March 27th. This represents a yield of 2.57%. The ex-dividend date is Thursday, February 28th. This is an increase from AstraZeneca's previous dividend of $68.40. The official announcement can be seen at this link. View AstraZeneca's Dividend History. When is AstraZeneca's next earnings date? AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for AstraZeneca. What price target have analysts set for AZN? 22 Wall Street analysts have issued 12-month target prices for AstraZeneca's shares. Their forecasts range from GBX 5,000 to GBX 8,500. On average, they anticipate AstraZeneca's stock price to reach GBX 6,397.70 in the next year. This suggests a possible upside of 9.3% from the stock's current price. View Analyst Price Targets for AstraZeneca. What is the consensus analysts' recommendation for AstraZeneca? 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 3 sell ratings, 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca. Has AstraZeneca been receiving favorable news coverage? News articles about AZN stock have trended very negative on Tuesday, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AstraZeneca earned a media sentiment score of -3.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. Who are some of AstraZeneca's key competitors? Some companies that are related to AstraZeneca include GlaxoSmithKline (GSK), Bayer (BAYN), Dechra Pharmaceuticals (DPH), Hutchison China MediTech (HCM), Mayne Pharma Group (MYX), Vectura Group (VEC), Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Opthea (OPT), Trilogy International Partners (TRL), Pharmaxis (PXS), Allergy Therapeutics (AGY), Vita Life Sciences (VLS) and Futura Medical (FUM). What other stocks do shareholders of AstraZeneca own? Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GlaxoSmithKline (GSK), Hain Celestial Group (HAIN), Vodafone Group (VOD), National Retail Properties (NNN), BP (BP), NVIDIA (NVDA), Marks and Spencer Group (MKS), British American Tobacco Plc Ads (BATS), Ford Motor (F) and Twitter (TWTR). Who are AstraZeneca's key executives? AstraZeneca's management team includes the folowing people: Mr. Pascal Soriot, CEO & Exec. Director (Age 60)Mr. Marc Dunoyer, CFO & Exec. Director (Age 67)Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 48)Thomas Kudsk Larsen, Head of Investor RelationsMr. Jefrey Pott, Gen. Counsel How do I buy shares of AstraZeneca? Shares of AZN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is AstraZeneca's stock price today? One share of AZN stock can currently be purchased for approximately GBX 5,856. How big of a company is AstraZeneca? AstraZeneca has a market capitalization of £76.82 billion and generates £22.40 billion in revenue each year. AstraZeneca employs 64,400 workers across the globe. What is AstraZeneca's official website? The official website for AstraZeneca is http://www.astrazeneca.com/. How can I contact AstraZeneca? AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000. MarketBeat Community Rating for AstraZeneca (LON AZN)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 1,384 (Vote Outperform)Underperform Votes: 1,572 (Vote Underperform)Total Votes: 2,956MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: Are all No-Load Funds Equal? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.